AstraZeneca Stock News

AstraZeneca and Daiichi Sankyo said on Thursday their breast cancer treatment Enhertu has been approved for use in England's ​state-run healthcare system, expanding access to a drug that ‌has been available in Scotland since 2023.

DALLAS--(BUSINESS WIRE)--Susan G. Komen®, the world's leading breast cancer organization, has announced a partnership with AstraZeneca to make patient navigation part of the national health care infrastructure to help patients overcome barriers, access timely treatment, reduce stress and improve adherence to cancer care plans. Komen and AstraZeneca will build a Navigation Infrastructure Collabo...

The Etcamah results came a week after the U.S. granted approval for the drug for advanced breast cancer upon the detection of a specific mutation.

AstraZeneca stock toppled in late trades Friday after the company's experimental breast cancer treatment failed to pass muster.

AstraZeneca ​said on ‌Friday ​its ​breast cancer ⁠drug ​failed to ​meet the ​main ​goal of improving ‌progression-free ⁠survival during ​a ​late-stage ⁠trial.

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) drew praise from Deutsche Bank for tozorakimab's lung disease data, but the broker paired its positive assessment with a bearish verdict on the shares. The shares traded at 11,634p, broadly flat, while the bank rated the drugmaker 'sell' with a target price of 11,500 pence.

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) drew Citi's backing after tozorakimab trial results, supporting an upside case of at least $7 billion in peak sales, roughly twice consensus. Behind the bullish call, phase III data presented at the European Respiratory Society meeting showed tozorakimab reduced flare-ups in chronic obstructive pulmonary disease (COPD).

Today we feature data from studies being presented at the ongoing European Respiratory Society Congress in Barcelona.